Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2017-06-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-17-0089PMID 28615297PMCID PMC6574129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.

  2016cited by this paper
• TOR Complexes and the Maintenance of Cellular Homeostasis.

  2016cited by this paper
• Optimal Management of Double-Hit Lymphoma.

  2016influential reference
• Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy

  2016cited by this paper
• Double hit lymphoma: from biology to therapeutic implications

  2016cited by this paper
• Splicing and Dicing MYC-Mediated Synthetic Lethality.

  2015cited by this paper
• The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.

  2015influential reference
• Clinical Controversies of Double-Hit Lymphoma

  2015cited by this paper
• Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.

  2015cited by this paper
• Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2

  2014cited by this paper
• Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

  2014cited by this paper
• Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

  2013cited by this paper
• Inhibition of mTOR Pathway Sensitizes Acute Myeloid Leukemia Cells to Aurora Inhibitors by Suppression of Glycolytic Metabolism

  2013cited by this paper
• Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.

  2013cited by this paper
• MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.

  2013cited by this paper
• A sensitive method to quantify senescent cancer cells.

  2013cited by this paper
• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  2013cited by this paper
• MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.

  2013cited by this paper
• A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.

  2012influential reference
• Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

  2012cited by this paper
• Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

  2012cited by this paper
• Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma Cells*

  2012cited by this paper
• Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

  2012cited by this paper
• Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.

  2011cited by this paper
• Novel therapeutics for aggressive non-Hodgkin's lymphoma.

  2011cited by this paper
• Update on aurora kinase targeted therapeutics in oncology

  2011cited by this paper
• Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53

  2011cited by this paper
• Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.

  2010cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

  2010cited by this paper
• Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion.

  2008cited by this paper
• Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.

  2008cited by this paper
• The Src family kinase Hck regulates mast cell activation by suppressing an inhibitory Src family kinase Lyn.

  2007cited by this paper
• Analysis of Aurora‐A and hMPS1 mitotic kinases in mantle cell lymphoma

  2006influential reference
• Aurora kinases, aneuploidy and cancer, a coincidence or a real link?

  2005cited by this paper
• Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures

  2005cited by this paper
• Progress in the development of selective inhibitors of Aurora kinases.

  2005cited by this paper
• Progress in the development of selective inhibitors of aurora kinases.

  2005cited by this paper
• The p38α/β MAPK functions as a molecular switch to activate the quiescent satellite cell

  2005cited by this paper
• Chronic lymphocytic leukemia : revelations from the B-cell receptor

  2004cited by this paper
• Chronic lymphocytic leukemia: revelations from the B-cell receptor.

  2004cited by this paper
• Interaction of Aurora-A and centrosomin at the microtubule-nucleating site in Drosophila and mammalian cells

  2003cited by this paper
• Function of Bruton’s Tyrosine Kinase during B Cell Development Is Partially Independent of Its Catalytic Activity 1

  2003cited by this paper
• Regulation of Aurora-A kinase on the mitotic spindle

  2003cited by this paper
• Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non‐Hodgkin's lymphoma

  2003cited by this paper
• The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.

  2002cited by this paper
• Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.

  2002cited by this paper
• CD20‐mediated apoptosis: signalling through lipid rafts

  2002cited by this paper
• The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.

  2000influential reference
• Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation

  1998cited by this paper
• Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement.

  1994cited by this paper
• Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells.

  1994cited by this paper

• Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations

  2026cites this paper
• DRUG AND SINGLE-CELL GENE EXPRESSION INTEGRATION IDENTIFIES SENSITIVE AND RESISTANT GLIOBLASTOMA CELL POPULATIONS

  2025cites this paper
• MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma

  2025cites this paper
• Mitochondrial-targeted iridium(III) complexes suppress tumor growth through inducting immunogenic cell death to activate immune response.

  2025cites this paper
• Ageing microenvironment mediates lymphocyte carcinogenesis and lymphoma drug resistance: From mechanisms to clinical therapy (Review)

  2024influential citation
• Polyploidy in Cancer: causal mechanisms, cancer-specific consequences, and emerging treatments.

  2024cites this paper
• Circulating lncRNA- and miRNA-Associated ceRNA Network as a Potential Prognostic Biomarker for Non-Hodgkin Lymphoma: A Bioinformatics Analysis and a Pilot Study

  2022cites this paper
• Future prospects for mitosis-targeted antitumor therapies.

  2021cites this paper
• Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?

  2021cites this paper
• Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway

  2021cites this paper
• Identification of Hub Genes and Key Pathways Associated with Peripheral T-cell Lymphoma

  2020cites this paper
• Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma

  2020cites this paper
• Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy.

  2020cites this paper
• The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines

  2019cites this paper
• Current perspectives on the treatment of double hit lymphoma

  2019cites this paper
• Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines

  2019cites this paper
• Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors

  2019cites this paper
• CS2164 exerts an antitumor effect against human Non‐Hodgkin's lymphomas in vitro and in vivo

  2018cites this paper
• Novel Aurora Kinase Inhibitor-Based Combination Therapies for PTCL

  2018cites this paper
• DNA methylation marks in peripheral blood and the risk of developing mature B cell neoplasms

  2018cites this paper
• Drug-induced resistance: nipping it in the ‘budding’

  2018cites this paper
• Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma

  2018cites this paper
• Acrofolione A and B, acetophenone dimers from Acronychia pendunculata, induce an apoptotic effect on human NALM‐6 pre‐B cell leukaemia cells

  2018cites this paper
• Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

  2018cites this paper
• Activation of S6 signaling is associated with cell survival and multinucleation in hyperplastic skin after epidermal loss of AURORA-A Kinase

  2018cites this paper
• Long noncoding RNA Lnc‑EGFR promotes cell proliferation and inhibits cell apoptosis via regulating the expression of EGFR in human tongue cancer.

  2017cites this paper
• Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway

  2017cites this paper
• Deguelin, an Aurora B Kinase Inhibitor, Exhibits Potent Anti-Tumor Effect in Human Esophageal Squamous Cell Carcinoma

  2017cites this paper